Mr Evan Scott Thompson, PA-C, ATC, AEMT | |
580 Court St, Keene, NH 03431-1729 | |
(603) 354-5400 | |
Not Available |
Full Name | Mr Evan Scott Thompson |
---|---|
Gender | Male |
Speciality | Physician Assistant |
Location | 580 Court St, Keene, New Hampshire |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1376941740 | NPI | - | NPPES |
0555 | Other | NH | NH STATE ATHLETIC TRAINING LICENSE |
30091A | Other | NH | NH DEPT. OF SAFETY; DIVISION OF FIRE STANDARDS & TRAINING AND EMS; BUREAU OF EMS |
2000012822 | Other | BOARD OF CERTIFICATION | |
A2022946 | Other | NH | NATIONAL REGISTRY OF EMERGENCY MEDICAL TECHNICIANS |
Mailing Address | Practice Location Address |
---|---|
Mr Evan Scott Thompson, PA-C, ATC, AEMT 1260 Elm St, Manchester, NH 03101-1305 Ph: (603) 314-1701 | Mr Evan Scott Thompson, PA-C, ATC, AEMT 580 Court St, Keene, NH 03431-1729 Ph: (603) 354-5400 |
News Archive
Scientists have only recently begun to speculate that what's referred to as junk DNA , the 96 percent of the human genome that doesn't encode for proteins and previously seemed to have no useful purpose , is present in the genome for an important reason.
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has been featured in an in-depth report by Griffin Securities, a New York-based brokerage firm, highlighting the importance of the role that cancer stem cell (CSCs) targeting technology such as that employed by its lead product candidate, ICT-121, may play in developing future cancer treatments.
EpiCareSRT announced today it has entered into a strategic partnership with Sensus Healthcare to take new aim at skin cancer by providing the first mobile service to bring low-dose superficial radiation therapy directly to the point-of-care in dermatology offices.
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor as well as first recipient of an endowed chair in the new Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a Citation Classic in the current issue of Clinical Chemistry. Hennekens was the founding principal investigator (PI) of the landmark Physician's Health Study and was the first to demonstrate that aspirin prevents a first heart attack.
Groundbreaking research demonstrates the ability of a specific form of Modified Citrus Pectin (MCP) to greatly enhance immune function.
› Verified 3 days ago